ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer

ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer

At the 2026 ESMO Congress, Professor Barbara Pistilli of Gustave Roussy Cancer Center, France, presented updated results from VIKTORIA-1 Study 2 in patients with PIK3CA-mutant disease. The study showed that both the gedatolisib triplet combination (gedatolisib + palbociclib + fulvestrant) and the doublet combination (gedatolisib + fulvestrant) significantly improved progression-free survival (PFS) compared with alpelisib plus fulvestrant, regardless of whether patients had visceral or liver metastases. Based on these findings, Oncology Frontier interviewed Professor Barbara Pistilli at the congress to discuss the subgroup analyses, safety data, and clinical implications of the study.
ESMO Insights | Professor Gustavo Werutsky: lidERA BC PRO Results Show Giredestrant Improves Efficacy While Preserving Quality of Life

ESMO Insights | Professor Gustavo Werutsky: lidERA BC PRO Results Show Giredestrant Improves Efficacy While Preserving Quality of Life

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27 (local time). At the meeting, Professor Gustavo Werutsky of Moinhos de Vento Hospital in Porto Alegre, Brazil, presented patient-reported outcome (PRO) data from the phase III lidERA BC study (Abstract No. 538RO). The study evaluated the efficacy and safety of giredestrant, an oral selective estrogen receptor degrader (SERD), as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative (ER+/HER2−) early breast cancer. The PRO analysis showed that, alongside a significant improvement in invasive disease-free survival (iDFS), giredestrant effectively preserved patients' health-related quality of life (HRQoL) and daily functioning, while significantly reducing the burden of side effects and the risk of treatment discontinuation. Following his presentation, Oncology Frontier invited Professor Gustavo Werutsky for an interview to discuss the key findings and clinical implications of the lidERA BC PRO data, as well as their potential impact on the future landscape of adjuvant endocrine therapy.
Professor Shuiping Yin: New Developments and Individualized Strategies in the Treatment of Advanced Renal Cell Carcinoma

Professor Shuiping Yin: New Developments and Individualized Strategies in the Treatment of Advanced Renal Cell Carcinoma

In the field of urologic oncology, systemic treatment for advanced renal cell carcinoma (RCC) has fully entered the era of targeted therapy combined with immunotherapy (targeted therapy–immunotherapy combinations). However, how to make precise, individualized treatment decisions for patients across different risk groups, and how to select the optimal subsequent-line regimen after treatment failure, remain major clinical challenges. At the recent 2026 CACAGU Academic Conference, Professor Shuiping Yin and Professor Zhaozhao Liang from the Department of Urology, The First Affiliated Hospital of Anhui Medical University, delivered an in-depth presentation entitled Individualized Treatment and Latest Research Advances in Advanced Renal Tumors. This article highlights the key points of their presentation and systematically reviews individualized first-line treatment decisions, investigations of triplet combinations, advances in second-line treatment, and surgical management of complex tumor thrombi.
10th West China Tianfu Academic Conference on Urologic Oncology | Professor Baijun Dong: From AR Inhibition to Combination Strategies Targeting Multiple Pathways—Exploring New Approaches to Overcoming Treatment Resistance in Prostate Cancer

10th West China Tianfu Academic Conference on Urologic Oncology | Professor Baijun Dong: From AR Inhibition to Combination Strategies Targeting Multiple Pathways—Exploring New Approaches to Overcoming Treatment Resistance in Prostate Cancer

The 10th West China Tianfu Academic Conference on Urologic Oncology was held in Chengdu from November 5 to 7, 2026. From conventional androgen receptor (AR) inhibitors to AR degraders, and further to combination strategies targeting AR alongside PARP and AKT inhibitors, pharmacological treatment for prostate cancer is shifting from single-target blockade toward coordinated pathway inhibition. However, treatment resistance remains a central challenge that cannot be overlooked. Against this backdrop, Oncology Frontier – UroStream invited Professor Baijun Dong from Renji Hospital, Shanghai Jiao Tong University School of Medicine, to share his insights into promising directions in AR-targeted drug development, combination treatment strategies, and pathways for the international development of innovative drugs originating in China.
10th West China Tianfu Academic Conference on Urologic Oncology | Professor Fufu Zheng: Focusing on KIM-1 and ctDNA to Explore New Approaches to Precision Diagnosis and Treatment of Renal Cancer

10th West China Tianfu Academic Conference on Urologic Oncology | Professor Fufu Zheng: Focusing on KIM-1 and ctDNA to Explore New Approaches to Precision Diagnosis and Treatment of Renal Cancer

The 10th West China Tianfu Academic Conference on Urologic Oncology was held in Chengdu from November 5 to 7, 2026. To date, renal cancer still lacks a biomarker comparable to PSA. Diagnosis relies on imaging, while postoperative management depends on follow-up, leaving a critical gap in the framework for precise risk stratification. Against this backdrop, Oncology Frontier – UroStream invited Professor Fufu Zheng from the First Affiliated Hospital of Sun Yat-sen University to share his insights on the most pressing biomarker needs in renal cancer, the clinical value of KIM-1 and ctDNA, how biomarkers can be incorporated into risk-stratified treatment, and the pathway from biomarker discovery to standardized clinical implementation.
ESMO Insights | Professor Hope S. Rugo: KEYNOTE-B49 Shows PFS Benefit with Immunotherapy Plus Chemotherapy in HR+/HER2− Advanced Breast Cancer

ESMO Insights | Professor Hope S. Rugo: KEYNOTE-B49 Shows PFS Benefit with Immunotherapy Plus Chemotherapy in HR+/HER2− Advanced Breast Cancer

At the 2026 ESMO Congress, Professor Hope S. Rugo of City of Hope Comprehensive Cancer Center, California, USA, presented the interim analysis (IA) and final analysis (FA) results of the KEYNOTE-B49 study. The findings showed that pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) in patients with PD-L1 CPS ≥1, HR-positive/HER2-negative advanced breast cancer (ABC). The PFS benefit was more pronounced in the subgroup with PD-L1 CPS ≥10. In addition, the immunotherapy combination more than tripled the 24-month PFS rate, with an overall manageable safety profile. These findings suggest that some patients with endocrine-resistant and more aggressive disease may benefit from immunotherapy. Oncology Frontier interviewed Professor Hope S. Rugo at the ESMO Congress to discuss the key findings from KEYNOTE-B49, the clinical benefits observed in specific subgroups, and the role of PD-L1 testing in guiding clinical practice.
Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care

Professor Susanna Kauhanen: Exploring Nordic Breast Reconstruction Practices and the Long-Term Value of Comprehensive Breast Cancer Care

Breast cancer is the most commonly diagnosed malignancy among women worldwide. With continued advances in systemic treatment and surgical techniques, patient survival has improved significantly, making postoperative quality of life and the restoration of physical and psychological well-being increasingly important components of comprehensive breast cancer care. Breast reconstruction is not only a concentrated expression of surgical expertise but also an important means of helping patients return to normal life, making it an integral part of breast cancer prevention and treatment.
Xinghai Forum | Professor Man Li: Advancing Precision and Collaborative Innovation in Comprehensive Cancer Care

Xinghai Forum | Professor Man Li: Advancing Precision and Collaborative Innovation in Comprehensive Cancer Care

To further promote standardized and precision-based cancer treatment, the 7th Dalian Xinghai Medical Forum Academic Conference on Comprehensive Cancer Treatment was jointly organized by the Beijing Cancer Prevention and Control Society and the Beijing Breast Cancer Prevention and Control Society, co-organized by the Oncology Branch of the Dalian Medical Association, and hosted by the Second Affiliated Hospital of Dalian Medical University. The conference was held in Dalian from November 6 to 8, 2026, in a hybrid online and in-person format. Under the theme "Focus on Precision, Collaborate for Innovation," the meeting brought together leading experts from across China in liver cancer, lung cancer, gastrointestinal tumors, breast cancer, lymphoma, gynecologic oncology, immunotherapy, and other fields. Participants delivered presentations on the latest clinical applications and research advances in cancer care. Oncology Frontier invited Professor Man Li of the Second Affiliated Hospital of Dalian Medical University, Chair of the Conference, to introduce the program and highlights of the meeting and share her perspectives on patient education and the research development of young physicians.